MacroGenics, Inc. is developing immunotherapeutics, including monoclonal antibodies, to treat patients with cancer, autoimmune disorders, allergy, or infectious diseases.
Anti-CD3 (teplizumab)
Next Generation, Fc-Optimized, Best-In-Class Mab
Anti-CD16
Capabilities